U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H29N3O8
Molecular Weight 499.5131
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SERDEXMETHYLPHENIDATE

SMILES

[H][C@@]1(CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)N[C@@H](CO)C([O-])=O)[C@H](C(=O)OC)C3=CC=CC=C3

InChI

InChIKey=UBZPNQRBUOBBLN-PWRODBHTSA-N
InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/t19-,20+,21+/m0/s1

HIDE SMILES / InChI

Molecular Formula C25H29N3O8
Molecular Weight 499.5131
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 3 / 3
E/Z Centers 0
Optical Activity UNSPECIFIED

Dexmethylphenidate is the dextrorotary form of methylphenidate. Dexmethylphenidate is marketed under the trade name Focalin. Focalin (dexmethylphenidate hydrochloride) is the d-threo-enantiomer of racemic methylphenidate hydrochloride, which is a 50/50 mixture of the d-threo and l-threoenantiomers. Focalin is a central nervous system (CNS) stimulant, available in three tablet strengths. Each tablet contains dexmethylphenidate hydrochloride 2.5, 5, or 10 mg for oral administration. Dexmethylphenidate is used as a treatment for ADHD, ideally in conjunction with psychological, educational, behavioral or other forms of treatment. Methylphenidate blocks dopamine uptake in central adrenergic neurons by blocking dopamine transport or carrier proteins. Methylphenidate acts at the brain stem arousal system and the cerebral cortex and causes increased sympathomimetic activity in the central nervous system. Methylphenidate is a catecholamine reuptake inhibitor that indirectly increases catecholaminergic neurotransmission by inhibiting the dopamine transporter (DAT) and norepinephrine transporter (NET), which are responsible for clearing catecholamines from the synapse, particularly in the striatum and meso-limbic system.

CNS Activity

Curator's Comment: Dexmethylphenidate is a central nervous system (CNS) stimulant

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
FOCALIN

Approved Use

Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD.

Launch Date

2001
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
23.72 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.13 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
10.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
120.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
131.9 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
79.8 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2.68 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.81 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
3.3 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DEXMETHYLPHENIDATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Other AEs: Vomiting, Agitation...
Other AEs:
Vomiting
Agitation
Tremor
Hyperreflexia
Muscle twitching
Convulsions
Euphoria
Confusion
Hallucinations
Delirium
Sweating
Flushing
Headache
Hyperpyrexia
Tachycardia
Palpitations
Cardiac arrhythmias
Hypertension
Mydriasis
Mucosal dryness
Rhabdomyolysis
Sources: Page: p.11
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Disc. AE: Twitching, Anorexia...
AEs leading to
discontinuation/dose reduction:
Twitching (1%)
Anorexia (1%)
Insomnia (1%)
Tachycardia (1%)
Insomnia (1.8%)
Sources: Page: p.7
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Disc. AE: Cardiac disorders, Stroke...
Other AEs: Increased blood pressure, Heart rate increased...
AEs leading to
discontinuation/dose reduction:
Cardiac disorders (grade 3-5)
Stroke (grade 3-5)
Myocardial infarction (grade 3-5)
Seizures
Raynaud's phenomenon
Other AEs:
Increased blood pressure
Heart rate increased
Psychotic symptom (grade 3-5)
Psychotic symptom
Manic symptom
Aggression
Growth suppression
Priapism
Erection prolonged
Vascular disorders
Visual disturbance
Sources: Page: p.1
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Disc. AE: Feeling jittery, Anorexia...
AEs leading to
discontinuation/dose reduction:
Feeling jittery (1.8%)
Anorexia (1.2%)
Anxiety (1.2%)
Sources: Page: p.8
AEs

AEs

AESignificanceDosePopulation
Agitation
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Cardiac arrhythmias
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Confusion
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Convulsions
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Delirium
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Euphoria
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Flushing
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hallucinations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Headache
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hyperpyrexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hyperreflexia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Hypertension
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Mucosal dryness
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Muscle twitching
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Mydriasis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Palpitations
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Rhabdomyolysis
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Sweating
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Tachycardia
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Tremor
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Vomiting
40 mg single, oral (min)
Overdose
Dose: 40 mg
Route: oral
Route: single
Dose: 40 mg
Sources: Page: p.11
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.11
Anorexia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Insomnia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Tachycardia 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Twitching 1%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Insomnia 1.8%
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.7
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.7
Aggression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Erection prolonged
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Growth suppression
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Heart rate increased
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Increased blood pressure
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Manic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Priapism
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Psychotic symptom
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Vascular disorders
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Visual disturbance
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Raynaud's phenomenon Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Seizures Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Psychotic symptom grade 3-5
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Cardiac disorders grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Myocardial infarction grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Stroke grade 3-5
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.1
Anorexia 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Anxiety 1.2%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Feeling jittery 1.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Recommended
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.8
unhealthy
Health Status: unhealthy
Condition: Attention Deficit Hyperactivity Disorder
Sources: Page: p.8
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
weak
yes
PubMed

PubMed

TitleDatePubMed
The use of a laboratory school protocol to evaluate concepts about efficacy and side effects of new formulations of stimulant medications.
2002
Neurobehavioral effects of racemic threo-methylphenidate and its D and L enantiomers in rats.
2003 Feb
D-Methylphenidate is non-genotoxic in in vitro and in vivo assays.
2003 May 9
A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
2004 Feb
Open-label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder.
2004 Winter
Attention deficit/hyperactivity disorder: pharmacotherapy.
2005 Jan
Differential effects of amphetamine isomers on dopamine release in the rat striatum and nucleus accumbens core.
2005 Mar
Dexmethylphenidate extended release: in attention-deficit hyperactivity disorder.
2006
[Medical treatments of hyperactive child: about the new pharmaceutical forms of methylphenidate marketed in France].
2006 Jan
Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
2006 Jul
[Pharmacotherapy of adult Attention Deficit/Hyperactivity Disorder (ADHD): a systematic review].
2007
Efficacy and safety of dexmethylphenidate extended-release capsules in adults with attention-deficit/hyperactivity disorder.
2007 Jun 15
Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription dug spending for children and adolescents: increasing relevance of health economic evidence.
2007 Nov 15
Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
2008 Jun
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
2008 May
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride.
2009
Psychopharmacology of ADHD in pediatrics: current advances and issues.
2009
Efficacy and safety of dexmethylphenidate extended-release capsules administered once daily to children with attention-deficit/hyperactivity disorder.
2009 Aug
Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder.
2009 Dec
Ixabepilone: a new treatment option for the management of taxane-resistant metastatic breast cancer.
2009 Jun 29
A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD).
2009 Jun 8
Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD.
2009 Mar
Focalin XR for ADHD.
2009 Mar 23
Pharmacotherapy for adult ADHD.
2009 May
Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial.
2009 Nov
Dexmethylphenidate for attention deficit hyperactivity disorder.
2009 Nov
Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
2010
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.
2010 Apr
Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention-deficit/hyperactivity disorder and Tourette's disorder.
2010 Aug
Use of psychostimulants in patients with dementia.
2010 Oct
Azido-iodo-N-benzyl derivatives of threo-methylphenidate (Ritalin, Concerta): Rational design, synthesis, pharmacological evaluation, and dopamine transporter photoaffinity labeling.
2011 Jan 1
Patents

Sample Use Guides

Focalin (Dexmethylphenidate) is administered twice daily, at least 4 hours apart. Focalin may be administered with or without food. The recommended starting dose of Focalin for patients who are not currently taking racemic methylphenidate, or for patients who are on stimulants other than methylphenidate, is 5 mg/day (2.5 mg twice daily). Dosage may be adjusted in 2.5 to 5 mg increments to a maximum of 20 mg/day (10 mg twice daily). In general, dosage adjustments may proceed at approximately weekly intervals.
Route of Administration: Oral
Dexmethylphenidate inhibition [3H]dopamine uptake at human DAT expressed in mouse N2A cells with IC50 156 nM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 13:40:47 GMT 2023
Edited
by admin
on Sat Dec 16 13:40:47 GMT 2023
Record UNII
0H8KZ470DW
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SERDEXMETHYLPHENIDATE
USAN   INN  
Official Name English
KP-415 INNER SALT
Code English
serdexmethylphenidate [INN]
Common Name English
SERDEXMETHYLPHENIDATE [USAN]
Common Name English
N-(1-((((2R)-2-((1R)-2-METHOXY-2-OXO-1-PHENYLETHYL)PIPERIDINE-1-CARBONYL)OXY)METHYL)PYRIDIN-1-IUM-3-CARBONYL)-L-SERINATE
Systematic Name English
Serdexmethylphenidate [WHO-DD]
Common Name English
PYRIDINIUM, 3-((((1S)-1-CARBOXY-2-HYDROXYETHYL)AMINO)CARBONYL)-1-(((((2R)-2-((1R)-2-METHOXY-2-OXO-1-PHENYLETHYL)-1-PIPERIDINYL)CARBONYL)OXY)METHYL)-
Systematic Name English
Classification Tree Code System Code
DEA NO. 1729
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
FDA ORPHAN DRUG 878522
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
Code System Code Type Description
CAS
2014450-84-9
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
ALTERNATIVE
SMS_ID
300000005913
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
CAS
1996626-29-9
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
FDA UNII
0H8KZ470DW
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
RXCUI
2562176
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
INN
10916
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
PUBCHEM
134823895
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
NCI_THESAURUS
C166420
Created by admin on Sat Dec 16 13:40:47 GMT 2023 , Edited by admin on Sat Dec 16 13:40:47 GMT 2023
PRIMARY
Related Record Type Details
EXCRETED UNCHANGED
URINE
SALT/SOLVATE -> PARENT
EXCRETED UNCHANGED
FECAL
BINDER->LIGAND
Related Record Type Details
METABOLITE ACTIVE -> PRODRUG
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Tmax PHARMACOKINETIC FASTED STATE
PHARMACOKINETIC
SINGLE DOSE ADMINISTRATION
PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC IN HEALTHY ADULT SUBJECTS
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC after AZSTARYS administration
PHARMACOKINETIC